Rexinoids are selective ligands for the nuclear receptors known as RXRs. They do not bind
to the receptors for all-trans-retinoic acid (RARs). Many new rexinoids have been synthesized and
then assayed for their ability to suppress proliferation of cancer cells, to inhibit activation of inflammatory
cells of the tumor microenvironment, and to prevent carcinogenesis in animal models relevant
to human disease. Here we review the literature on the effects of 4 such rexinoids: bexarotene,
LG100268, LG101506, and NRX194204. These rexinoids also have potent synergistic effects when
used in combination with other active pharmacological agents, and practical clinical applications
would benefit from these actions.
Keywords: RXR, Bexarotene, LG100268, Inflammation, Carcinogenesis, Combination therapy.
Rights & PermissionsPrintExport